Event
FDA orders GLP-1 drug warnings over blindness risk
The US FDA ordered GLP-1 medicine manufacturers to add warnings about a risk of permanent blindness.
The United States Food and Drug Administration has ordered manufacturers of GLP-1 medicines, including semaglutide and tirzepatide, to include warnings about potential eye risks. These drugs, used for type 2 diabetes and weight loss, may increase the risk of non-arteritic anterior ischemic optic neuropathy, a disorder that can cause permanent blindness.
The FDA is a federal agency within the United States Department of Health and Human Services responsible for supervising pharmaceutical drugs and public health.
Headlines and summaries are written by AI for Outer News (RS Elite Pro s.r.o.) from Wikipedia's text and are not reviewed by a person. They can contain mistakes: before you rely on one, read the original.
Read on WikipediaSource: Wikipedia: Current events · CC BY-SA 4.0